Alerts & Corrections

AHFS Patient Medication Information Update – April 2016

21 April, 2016 no responses

The April update to the AHFS Patient Medication Information (PMI) database has been published. Highlights of this month’s update include:

New AHFS PMI Monographs

  • Buprenorphine Buccal (Belbuca®), indicated for severe chronic pain
  • Emtricitabine/Rilpivirine/Tenofovir (Complera®), indicated for HIV infection
  • Lesinurad (Zurampic®), indicated for hyperuricemia in people with gout
  • Posaconazole Injection (Noxafil®), indicated for prevention of fungal infections in people with weakened ability to fight infections

FDA MedWatch Alerts

  • New safety warnings for opioids
  • Risk of heart failure for alogliptin and saxagliptin
  • New safety warning for metformin in patients with reduced kidney function

The New AHFS Clinical Drug Information – Coming Soon

13 January, 2016 no responses

AHFS-CDI-200x242

Help Faster. Heal Smarter.
AHFS. Real time drug information to advance care.

For 58 years, you’ve counted on AHFS to make the most trusted drug and safety recommendations. Now, make those recommendations…FAST.

Coming in 2016, the new AHFS® Clinical Drug Information™ is your comprehensive, interactive treatment and drug therapy solution to optimize your time and advance care.

  • Real-time drug and safety updates
  • Quick clinical window—fast access to the most comprehensive, authoritative evidence-based drug information
  • Direct links to more than 60,000 supporting evidence sources
  • In-depth, unbiased coverage of off-label uses
  • Seamlessly incorporated FDA safety data
  • 87,000 references, including published research, therapeutic guidelines, and prescribing information
  • Designated official US compendium

Individual pricing starts as low as $10 per month for members and $15 per month for non-members. Institutional trials are available. Contact us for pricing information.

1 … 20 21 22
© 2022, American Society of Health-System Pharmacists®. All rights reserved.